{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:36:11Z","timestamp":1792470971132,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jhepr.2025.101521","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T06:03:37Z","timestamp":1753164217000},"page":"101521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Proteomic signatures reflect effects of semaglutide treatment for MASH"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-7910","authenticated-orcid":false,"given":"Henning","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5695-8419","authenticated-orcid":false,"given":"Steen","family":"Ladelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6131-3981","authenticated-orcid":false,"given":"Michelle T.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sune Boris","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-5748","authenticated-orcid":false,"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhepr.2025.101521_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101521_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.amjms.2023.11.007","article-title":"Metabolic dysfunction associated steatotic liver disease: current practice, screening guidelines and management in the primary care setting","volume":"367","author":"Gupta","year":"2024","journal-title":"Am J Med Sci"},{"issue":"8","key":"10.1016\/j.jhepr.2025.101521_bib3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101521_bib4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/liv.14825","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis","volume":"41","author":"Schattenberg","year":"2021","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101521_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","article-title":"An international multidisciplinary consensus statement on MAFLD and the risk of CVD","volume":"17","author":"Zhou","year":"2023","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101521_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cld.650","article-title":"Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: from bench to bedside","volume":"10","author":"Armstrong","year":"2017","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"10","key":"10.1016\/j.jhepr.2025.101521_bib7","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","article-title":"Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation","volume":"17","author":"Huber","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101521_bib8","article-title":"Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study","volume":"2","author":"O'Hara","year":"2020","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101521_bib9","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jhep.2020.07.020","article-title":"On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis","volume":"73","author":"Schattenberg","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101521_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11695-007-9041-2","article-title":"Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass","volume":"17","author":"Arun","year":"2007","journal-title":"Obes Surg"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101521_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000281205","article-title":"Unusual presentation of metastatic carcinoma of prostate","volume":"41","author":"Chiu","year":"1986","journal-title":"Urol Int"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101521_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101521_bib13","unstructured":"U.S. Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Accessed June 6, 2025."},{"issue":"4","key":"10.1016\/j.jhepr.2025.101521_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101521_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase II randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101521_bib16","series-title":"Highlights of Prescribing Information. OZEMPIC (semaglutide) injection, for subcutaneous use","year":"2020"},{"key":"10.1016\/j.jhepr.2025.101521_bib17","series-title":"Highlights of Prescribing Information. RYBELSUS (semaglutide) tablets, for oral use","year":"2019"},{"key":"10.1016\/j.jhepr.2025.101521_bib18","series-title":"Highlights of Prescribing Information. WEGOVY (semaglutide) injection, for subcutaneous use","year":"2021"},{"issue":"12","key":"10.1016\/j.jhepr.2025.101521_bib19","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jhepr.2025.101521_bib20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101521_bib21","unstructured":"Somalogic. SomaSignal tests. https:\/\/somalogic.com\/somasignal-tests-for-research-use\/. Accessed June 6, 2025."},{"issue":"4","key":"10.1016\/j.jhepr.2025.101521_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jhep.2022.11.029","article-title":"Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease","volume":"78","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101521_bib23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/hep4.1670","article-title":"SOMAscan proteomics identifies serum biomarkers associated with liver fibrosis in patients with NASH","volume":"5","author":"Luo","year":"2021","journal-title":"Hepatol Commun"},{"issue":"11","key":"10.1016\/j.jhepr.2025.101521_bib24","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10278","key":"10.1016\/j.jhepr.2025.101521_bib25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101521_bib26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101521_bib27","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101521_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101521_bib29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101521_bib30","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/dom.15016","article-title":"Nonalcoholic fatty liver disease from a primary care perspective","volume":"25","author":"Clark","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.jhepr.2025.101521_bib31","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/apt.14976","article-title":"Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany","volume":"48","author":"Labenz","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101521_bib32","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/hep.26465","article-title":"Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients","volume":"58","author":"Noureddin","year":"2013","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jhepr.2025.101521_bib33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101521_bib34","article-title":"Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial","volume":"5","author":"Brown","year":"2023","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101521_bib35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101521_bib36","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101521_bib37","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2025.101521_bib38","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc23-Sint","article-title":"Introduction and methodology: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.jhepr.2025.101521_bib39","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4254\/wjh.v13.i11.1688","article-title":"Abnormal liver enzymes: a review for clinicians","volume":"13","author":"Kalas","year":"2021","journal-title":"World J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101521_bib40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.21037\/hbsn-23-346","article-title":"Fibroscan-AST (FAST) score and other non-invasive tests for the diagnosis of fibrotic non-alcoholic steatohepatitis","volume":"12","author":"Chan","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"20","key":"10.1016\/j.jhepr.2025.101521_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015473","article-title":"Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments","volume":"24","author":"Yanai","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101521_bib42","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925002009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925002009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:12:30Z","timestamp":1762632750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925002009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2589555925002009"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101521","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteomic signatures reflect effects of semaglutide treatment for MASH","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101521"}}